IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.
Schardt JS, Walseng E, Le K, Yang C, Shah P, Fu Y, Alam K, Kelton CR, Gu Y, Huang F, Lin J, Liu W, Dippel A, Zhang H, Mulgrew K, Pryts S, Chennupati V, Chen HC, Denham J, Chen X, Pradhan P, Wu Y, Hardman C, Zhao C, Kierny M, Song Y, Dovedi SJ, Cemerski S, Mazor Y.
Schardt JS, et al. Among authors: zhao c.
MAbs. 2024 Jan-Dec;16(1):2395499. doi: 10.1080/19420862.2024.2395499. Epub 2024 Aug 28.
MAbs. 2024.
PMID: 39205483
Free PMC article.